apremilast vs Roflumilast (Zoryve foam)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Psoriasis

Shared mechanism: PDE4 · full Psoriasis pipeline

apremilast · Otezla

Marketed by Amgen

Approved in Psoriasissmall molecule
Reliable signal

NCT01194219 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial of 844 participants, with 562 assigned to apremilast and 282 to placebo. The primary clinical endpoint was met: PASI-75 response at Week 16 was 33.1% with apremilast versus 5.3% with placebo (p<0.0001).

Next expected readout: January 2027 · NCT07908641 (registry estimate)

Reported efficacy

Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 (Baseline to Week 16): Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 (Baseline to Week 16): Apremilast 33.1% vs Placebo 11.5% (met)

Result source: NCT03701763

Roflumilast (Zoryve foam)

Marketed by Arcutis Biotherapeutics and partners

Approved in Psoriasissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Psoriasis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointapremilastRoflumilast (Zoryve foam)
PASI 7533.1% vs 5.3%+27.8 vs placebowk 16 · n 562NCT01194219
10 other results
  • 28.8% vs 5.8% wk 16 · n 274 · Phase 3 · primary NCT01232283
  • 39.8% vs 11.9% wk 16 · n 83 · Phase 3 · primary NCT01690299
  • 45.4% vs 16.1% wk 16 · n 163 · Phase 3 · secondary NCT03701763
  • 28.2% vs 7.1% 30 mg BID · wk 16 · n 85 · Phase 2 · primary NCT01988103
  • 40.9% vs 5.7% 30 mg BID · wk 16 · n 88 · Phase 2 · primary NCT00773734
  • 23.5% vs 7.1% 20 mg BID · wk 16 · n 85 · Phase 2 · primary NCT01988103
  • 28.7% vs 5.7% 20 mg BID · wk 16 · n 87 · Phase 2 · primary NCT00773734
  • 11.2% vs 5.7% 10 mg BID · wk 16 · n 89 · Phase 2 · primary NCT00773734
  • 21.6% vs 8.2% wk 16 · n 148 · Phase 4 · secondary NCT02425826
  • 84.7% vs 18.8% wk 16 · n 118 · Phase 4 · secondary NCT04908475
50.1% vs 16.8%+33.3 vs placebo0.3% foam · wk 8 · n 281NCT05028582
PASI 9055.9% vs 5.1%vs APRwk 16 · n 118NCT04908475
3 other results
  • 11.4% vs 1.1% 30 mg BID · wk 16 · n 88 · Phase 2 · secondary NCT00773734
  • 9.2% vs 1.1% 20 mg BID · wk 16 · n 87 · Phase 2 · secondary NCT00773734
  • 4.5% vs 1.1% 10 mg BID · wk 16 · n 89 · Phase 2 · secondary NCT00773734
—Not reported
PASI 100—Not posted · NCT03168256—Not reported
sPGA 0/121.6% vs 4.1%+17.5 vs placebo30 mg · wk 16 · n 297NCT03721172
12 other results
  • 33.1% vs 11.5% wk 16 · n 163 · Phase 3 · primary NCT03701763
  • 21.7% vs 3.9% 30 mg BID · wk 16 · n 562 · Phase 3 · secondary NCT01194219
  • 22.2% vs 6.9% 30 mg · wk 16 · n 143 · Phase 3 · secondary NCT03777436
  • 20.4% vs 4.4% wk 16 · n 274 · Phase 3 · secondary NCT01232283
  • 21.7% vs 3.6% wk 16 · n 83 · Phase 3 · secondary NCT01690299
  • 75.4% vs 18.4% wk 16 · n 118 · Phase 4 · primary NCT04908475
  • 29.6% vs 8.8% 30 mg BID · wk 16 · n 71 · Phase 2 · secondary NCT01988103
  • 33.7% vs 12.6% 30 mg · wk 16 · n 83 · Phase 2 · secondary NCT00773734
  • 23.9% vs 8.8% 20 mg BID · wk 16 · n 71 · Phase 2 · secondary NCT01988103
  • 25% vs 12.6% 20 mg · wk 16 · n 80 · Phase 2 · secondary NCT00773734
  • 10.5% vs 12.6% 10 mg · wk 16 · n 86 · Phase 2 · secondary NCT00773734
  • 30.4% vs 9.6% wk 16 · n 148 · Phase 4 · secondary NCT02425826
—Not reported
DLQI, change-6.6 vs -2.1−4.5 vs placebo30 mg BID · wk 16 · n 556NCT01194219
11 other results
  • -5.3 vs -2.6 30 mg · wk 16 · n 117 · Phase 3 · secondary NCT03777436
  • -5.2 vs -2.4 30 mg · wk 16 · n 261 · Phase 3 · secondary NCT03721172
  • -6.7 vs -2.7 wk 16 · n 267 · Phase 3 · secondary NCT01232283
  • -8.4 vs -3.9 30 mg · wk 16 · n 79 · Phase 3 · secondary NCT01690299
  • -8.7 vs -3.4 30 mg · wk 16 · n 185 · Phase 4 · secondary NCT03774875
  • -2.2 vs 1.3 30 mg BID · wk 16 · n 85 · Phase 2 · secondary NCT01988103
  • -4.4 vs -1.9 30 mg BID · wk 16 · n 83 · Phase 2 · secondary NCT00773734
  • -0.5 vs 1.3 20 mg BID · wk 16 · n 85 · Phase 2 · secondary NCT01988103
  • -5.9 vs -1.9 20 mg BID · wk 16 · n 78 · Phase 2 · secondary NCT00773734
  • -3.2 vs -1.9 10 mg BID · wk 16 · n 87 · Phase 2 · secondary NCT00773734
  • -4.8 vs -2.4 wk 16 · n 144 · Phase 4 · secondary NCT02425826
—Not reported

PASI 75

apremilast
33.1% vs 5.3%+27.8 vs placebowk 16 · n 562NCT01194219
10 other results
  • 28.8% vs 5.8% wk 16 · n 274 · Phase 3 · primary NCT01232283
  • 39.8% vs 11.9% wk 16 · n 83 · Phase 3 · primary NCT01690299
  • 45.4% vs 16.1% wk 16 · n 163 · Phase 3 · secondary NCT03701763
  • 28.2% vs 7.1% 30 mg BID · wk 16 · n 85 · Phase 2 · primary NCT01988103
  • 40.9% vs 5.7% 30 mg BID · wk 16 · n 88 · Phase 2 · primary NCT00773734
  • 23.5% vs 7.1% 20 mg BID · wk 16 · n 85 · Phase 2 · primary NCT01988103
  • 28.7% vs 5.7% 20 mg BID · wk 16 · n 87 · Phase 2 · primary NCT00773734
  • 11.2% vs 5.7% 10 mg BID · wk 16 · n 89 · Phase 2 · primary NCT00773734
  • 21.6% vs 8.2% wk 16 · n 148 · Phase 4 · secondary NCT02425826
  • 84.7% vs 18.8% wk 16 · n 118 · Phase 4 · secondary NCT04908475
Roflumilast (Zoryve foam)
50.1% vs 16.8%+33.3 vs placebo0.3% foam · wk 8 · n 281NCT05028582

PASI 90

apremilast
55.9% vs 5.1%vs APRwk 16 · n 118NCT04908475
3 other results
  • 11.4% vs 1.1% 30 mg BID · wk 16 · n 88 · Phase 2 · secondary NCT00773734
  • 9.2% vs 1.1% 20 mg BID · wk 16 · n 87 · Phase 2 · secondary NCT00773734
  • 4.5% vs 1.1% 10 mg BID · wk 16 · n 89 · Phase 2 · secondary NCT00773734
Roflumilast (Zoryve foam)
—Not reported

PASI 100

apremilast
—Not posted · NCT03168256
Roflumilast (Zoryve foam)
—Not reported

sPGA 0/1

apremilast
21.6% vs 4.1%+17.5 vs placebo30 mg · wk 16 · n 297NCT03721172
12 other results
  • 33.1% vs 11.5% wk 16 · n 163 · Phase 3 · primary NCT03701763
  • 21.7% vs 3.9% 30 mg BID · wk 16 · n 562 · Phase 3 · secondary NCT01194219
  • 22.2% vs 6.9% 30 mg · wk 16 · n 143 · Phase 3 · secondary NCT03777436
  • 20.4% vs 4.4% wk 16 · n 274 · Phase 3 · secondary NCT01232283
  • 21.7% vs 3.6% wk 16 · n 83 · Phase 3 · secondary NCT01690299
  • 75.4% vs 18.4% wk 16 · n 118 · Phase 4 · primary NCT04908475
  • 29.6% vs 8.8% 30 mg BID · wk 16 · n 71 · Phase 2 · secondary NCT01988103
  • 33.7% vs 12.6% 30 mg · wk 16 · n 83 · Phase 2 · secondary NCT00773734
  • 23.9% vs 8.8% 20 mg BID · wk 16 · n 71 · Phase 2 · secondary NCT01988103
  • 25% vs 12.6% 20 mg · wk 16 · n 80 · Phase 2 · secondary NCT00773734
  • 10.5% vs 12.6% 10 mg · wk 16 · n 86 · Phase 2 · secondary NCT00773734
  • 30.4% vs 9.6% wk 16 · n 148 · Phase 4 · secondary NCT02425826
Roflumilast (Zoryve foam)
—Not reported

DLQI, change

apremilast
-6.6 vs -2.1−4.5 vs placebo30 mg BID · wk 16 · n 556NCT01194219
11 other results
  • -5.3 vs -2.6 30 mg · wk 16 · n 117 · Phase 3 · secondary NCT03777436
  • -5.2 vs -2.4 30 mg · wk 16 · n 261 · Phase 3 · secondary NCT03721172
  • -6.7 vs -2.7 wk 16 · n 267 · Phase 3 · secondary NCT01232283
  • -8.4 vs -3.9 30 mg · wk 16 · n 79 · Phase 3 · secondary NCT01690299
  • -8.7 vs -3.4 30 mg · wk 16 · n 185 · Phase 4 · secondary NCT03774875
  • -2.2 vs 1.3 30 mg BID · wk 16 · n 85 · Phase 2 · secondary NCT01988103
  • -4.4 vs -1.9 30 mg BID · wk 16 · n 83 · Phase 2 · secondary NCT00773734
  • -0.5 vs 1.3 20 mg BID · wk 16 · n 85 · Phase 2 · secondary NCT01988103
  • -5.9 vs -1.9 20 mg BID · wk 16 · n 78 · Phase 2 · secondary NCT00773734
  • -3.2 vs -1.9 10 mg BID · wk 16 · n 87 · Phase 2 · secondary NCT00773734
  • -4.8 vs -2.4 wk 16 · n 144 · Phase 4 · secondary NCT02425826
Roflumilast (Zoryve foam)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety

Coverage. apremilast: 7 of 7 rows · Roflumilast (Zoryve foam): 6 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricapremilast
Rows use multiple source trials
Roflumilast (Zoryve foam)
Itch NRS
responder rate · % of participants
Induction
47.3% (n=122) vs 19.6% (n=121) placebo @ 16wk30 mga,b,c
NCT03777436 · Phase 3
63.1% (n=203) vs 30.1% (n=110) placebo @ 8wk0.3% foama,b,c
NCT05028582 · Phase 3
Itch NRS
absolute change · score
Induction
-2.5 vs -0.9 placebo score @ 16wk30 mgd,a,b,e
NCT03774875 · Phase 4 · registry result, not featured evidence
-1.08 vs -0.53 placebo score @ 1wk0.3% foamd,a,b,e
NCT05028582 · Phase 3
PASI
absolute change · score
Induction
-3.47 vs -0.54 placebo score @ 16wk30 mga,b,f
NCT03721172 · Phase 3
-2.31 vs -1.03 placebo score @ 2wk0.3% foama,b,f
NCT05028582 · Phase 3
Dropout rate
—30 mg BIDg
NCT01194219 · Phase 3
show 67 more results
10.5%30 mg BID
NCT01194219 · Phase 3 · monotherapy
—30 mg BID
NCT01194219 · Phase 3
—30 mg BID
NCT01194219 · Phase 3
13.1%Apremilast
NCT01232283 · Phase 3
—Apremilast: Weeks 0-16 (PBO-Contro
NCT01232283 · Phase 3
—Apremilast: Weeks 0-260 (APR- Expo
NCT01232283 · Phase 3
—30 mg
NCT03123471 · Phase 3
16.4%Apremilast
NCT03123471 · Phase 3
—Apremilast /Apremilast (APR Exposu
NCT03123471 · Phase 3
—Apremilast Total (APR Exposure Per
NCT03123471 · Phase 3
—30 mg
NCT03777436 · Phase 3
16.8%30 mg
NCT03777436 · Phase 3
—30 mg BID
NCT03701763 · Phase 3
—30 mg BID
NCT03701763 · Phase 3
—20 mg BID
NCT03701763 · Phase 3
—20 mg BID
NCT03701763 · Phase 3
8.6%Apremilast
NCT03701763 · Phase 3
—BID
NCT03701763 · Phase 3
—BID
NCT03701763 · Phase 3
13.1%30 mg
NCT03721172 · Phase 3
—Apremalist: Placebo-controlled Pha
NCT03721172 · Phase 3
—Period A: RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB, NR
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: RZB/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
50%
NCT03022617 · Phase 4 · registry result, not featured evidence
17.8%30 mg
NCT03774875 · Phase 4 · registry result, not featured evidence
—30 mg
NCT03774875 · Phase 4 · registry result, not featured evidence
—30 mg
NCT03774875 · Phase 4 · registry result, not featured evidence
44.3%
NCT03082729 · Phase 4 · registry result, not featured evidence
54%
NCT03587194 · Phase 4 · registry result, not featured evidence · combination
5%
NCT03000309 · Phase 4 · registry result, not featured evidence
18.2%Apremilast
NCT02425826 · Phase 4 · registry result, not featured evidence
—Placebo-Controlled Phase: Apremila
NCT02425826 · Phase 4 · registry result, not featured evidence
22%
NCT02400749 · Phase 4 · registry result, not featured evidence
71.4%30 mg BID
NCT02412644 · Phase 4 · registry result, not featured evidence · combination
50%30 mg BID
NCT02412644 · Phase 4 · registry result, not featured evidence
—30 mg BID
NCT02412644 · Phase 4 · registry result, not featured evidence
—30 mg BID
NCT02412644 · Phase 4 · registry result, not featured evidence
—30 mg
NCT03930186 · Phase 3 · registry result, not featured evidence
7.9%Apremilast
NCT03930186 · Phase 3 · registry result, not featured evidence
—30 mg
NCT01690299 · Phase 3 · registry result, not featured evidence
7.2%Apremilast Plus Placebo Injection
NCT01690299 · Phase 3 · registry result, not featured evidence
—Apremilast Plus Placebo Injection
NCT01690299 · Phase 3 · registry result, not featured evidence
—Apremilast/Apremilast
NCT01690299 · Phase 3 · registry result, not featured evidence
17.9%
NCT03442088 · Phase 2 · registry result, not featured evidence
12.5%30 mg
NCT02576678 · Phase 2 · registry result, not featured evidence
38.5%20 mg
NCT02576678 · Phase 2 · registry result, not featured evidence
23.8%20 mg
NCT02576678 · Phase 2 · registry result, not featured evidence
—30 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
—30 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
—20 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
—20 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
20.5%30 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
—30 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
—30 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
24.1%20 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
—20 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
—20 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
11.2%10 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
—10 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
—10 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
—20 mg
NCT00521339 · Phase 2 · registry result, not featured evidence
38.7%20 mg
NCT00521339 · Phase 2 · registry result, not featured evidence
—20 mg/20 mg
NCT00521339 · Phase 2 · registry result, not featured evidence
—20 mg/30 mg
NCT00521339 · Phase 2 · registry result, not featured evidence
11%0.3% foamg
NCT05028582 · Phase 3
show 1 more result
11.5%
NCT04128007 · Phase 2
Discontinued due to AEs
—30 mg BIDg
NCT01194219 · Phase 3
show 67 more results
4.1%30 mg BID
NCT01194219 · Phase 3 · monotherapy
—30 mg BID
NCT01194219 · Phase 3
—30 mg BID
NCT01194219 · Phase 3
4.4%Apremilast
NCT01232283 · Phase 3
—Apremilast: Weeks 0-16 (PBO-Contro
NCT01232283 · Phase 3
—Apremilast: Weeks 0-260 (APR- Expo
NCT01232283 · Phase 3
—30 mg
NCT03123471 · Phase 3
4%Apremilast
NCT03123471 · Phase 3
—Apremilast /Apremilast (APR Exposu
NCT03123471 · Phase 3
—Apremilast Total (APR Exposure Per
NCT03123471 · Phase 3
—30 mg
NCT03777436 · Phase 3
7%30 mg
NCT03777436 · Phase 3
—30 mg BID
NCT03701763 · Phase 3
—30 mg BID
NCT03701763 · Phase 3
—20 mg BID
NCT03701763 · Phase 3
—20 mg BID
NCT03701763 · Phase 3
3.1%Apremilast
NCT03701763 · Phase 3
—BID
NCT03701763 · Phase 3
—BID
NCT03701763 · Phase 3
2.4%30 mg
NCT03721172 · Phase 3
—Apremalist: Placebo-controlled Pha
NCT03721172 · Phase 3
—Period A: RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB, NR
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: RZB/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—
NCT03022617 · Phase 4 · registry result, not featured evidence
8.6%30 mg
NCT03774875 · Phase 4 · registry result, not featured evidence
—30 mg
NCT03774875 · Phase 4 · registry result, not featured evidence
—30 mg
NCT03774875 · Phase 4 · registry result, not featured evidence
5.7%
NCT03082729 · Phase 4 · registry result, not featured evidence
—
NCT03587194 · Phase 4 · registry result, not featured evidence · combination
—
NCT03000309 · Phase 4 · registry result, not featured evidence
3.4%Apremilast
NCT02425826 · Phase 4 · registry result, not featured evidence
—Placebo-Controlled Phase: Apremila
NCT02425826 · Phase 4 · registry result, not featured evidence
6%
NCT02400749 · Phase 4 · registry result, not featured evidence
—30 mg BID
NCT02412644 · Phase 4 · registry result, not featured evidence · combination
—30 mg BID
NCT02412644 · Phase 4 · registry result, not featured evidence
—30 mg BID
NCT02412644 · Phase 4 · registry result, not featured evidence
—30 mg BID
NCT02412644 · Phase 4 · registry result, not featured evidence
—30 mg
NCT03930186 · Phase 3 · registry result, not featured evidence
3.9%Apremilast
NCT03930186 · Phase 3 · registry result, not featured evidence
—30 mg
NCT01690299 · Phase 3 · registry result, not featured evidence
2.4%Apremilast Plus Placebo Injection
NCT01690299 · Phase 3 · registry result, not featured evidence
—Apremilast Plus Placebo Injection
NCT01690299 · Phase 3 · registry result, not featured evidence
—Apremilast/Apremilast
NCT01690299 · Phase 3 · registry result, not featured evidence
3.6%
NCT03442088 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT02576678 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT02576678 · Phase 2 · registry result, not featured evidence
9.5%20 mg
NCT02576678 · Phase 2 · registry result, not featured evidence
—30 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
—30 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
—20 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
—20 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
11.4%30 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
—30 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
—30 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
9.2%20 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
—20 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
—20 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
1.1%10 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
—10 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
—10 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
—20 mg
NCT00521339 · Phase 2 · registry result, not featured evidence
6.5%20 mg
NCT00521339 · Phase 2 · registry result, not featured evidence
—20 mg/20 mg
NCT00521339 · Phase 2 · registry result, not featured evidence
—20 mg/30 mg
NCT00521339 · Phase 2 · registry result, not featured evidence
1.8%0.3% foamg
NCT05028582 · Phase 3
show 1 more result
2.5%
NCT04128007 · Phase 2
Serious AEs
—30 mg BIDg
NCT01194219 · Phase 3
show 67 more results
—30 mg BID
NCT01194219 · Phase 3 · monotherapy
9.2%30 mg BID
NCT01194219 · Phase 3
2.1%30 mg BID
NCT01194219 · Phase 3
—Apremilast
NCT01232283 · Phase 3
1.8%Apremilast: Weeks 0-16 (PBO-Contro
NCT01232283 · Phase 3
11.6%Apremilast: Weeks 0-260 (APR- Expo
NCT01232283 · Phase 3
1%30 mg
NCT03123471 · Phase 3
—Apremilast
NCT03123471 · Phase 3
3%Apremilast /Apremilast (APR Exposu
NCT03123471 · Phase 3
2.5%Apremilast Total (APR Exposure Per
NCT03123471 · Phase 3
0.9%30 mg
NCT03777436 · Phase 3
2.1%30 mg
NCT03777436 · Phase 3
1.8%30 mg BID
NCT03701763 · Phase 3
0%30 mg BID
NCT03701763 · Phase 3
0%20 mg BID
NCT03701763 · Phase 3
2.5%20 mg BID
NCT03701763 · Phase 3
—Apremilast
NCT03701763 · Phase 3
0.9%BID
NCT03701763 · Phase 3
1.2%BID
NCT03701763 · Phase 3
0.3%30 mg
NCT03721172 · Phase 3
2.2%Apremalist: Placebo-controlled Pha
NCT03721172 · Phase 3
0.8%Period A: RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
0%Period B: APR/APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
2.9%Period B: APR/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
—Period B: APR/RZB, NR
NCT04908475 · Phase 4 · registry result, not featured evidence
6.9%Period B: RZB/RZB
NCT04908475 · Phase 4 · registry result, not featured evidence
8.3%
NCT03022617 · Phase 4 · registry result, not featured evidence
—30 mg
NCT03774875 · Phase 4 · registry result, not featured evidence
5.4%30 mg
NCT03774875 · Phase 4 · registry result, not featured evidence
4.3%30 mg
NCT03774875 · Phase 4 · registry result, not featured evidence
8.6%
NCT03082729 · Phase 4 · registry result, not featured evidence
3.2%
NCT03587194 · Phase 4 · registry result, not featured evidence · combination
0%
NCT03000309 · Phase 4 · registry result, not featured evidence
—Apremilast
NCT02425826 · Phase 4 · registry result, not featured evidence
2%Placebo-Controlled Phase: Apremila
NCT02425826 · Phase 4 · registry result, not featured evidence
6%
NCT02400749 · Phase 4 · registry result, not featured evidence
—30 mg BID
NCT02412644 · Phase 4 · registry result, not featured evidence · combination
—30 mg BID
NCT02412644 · Phase 4 · registry result, not featured evidence
0%30 mg BID
NCT02412644 · Phase 4 · registry result, not featured evidence
3.4%30 mg BID
NCT02412644 · Phase 4 · registry result, not featured evidence
2.6%30 mg
NCT03930186 · Phase 3 · registry result, not featured evidence
—Apremilast
NCT03930186 · Phase 3 · registry result, not featured evidence
7.2%30 mg
NCT01690299 · Phase 3 · registry result, not featured evidence
—Apremilast Plus Placebo Injection
NCT01690299 · Phase 3 · registry result, not featured evidence
3.6%Apremilast Plus Placebo Injection
NCT01690299 · Phase 3 · registry result, not featured evidence
—Apremilast/Apremilast
NCT01690299 · Phase 3 · registry result, not featured evidence
0%
NCT03442088 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT02576678 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT02576678 · Phase 2 · registry result, not featured evidence
4.8%20 mg
NCT02576678 · Phase 2 · registry result, not featured evidence
0%30 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
1.7%30 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
4.7%20 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
9.1%20 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
—30 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
7.3%30 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
4.5%30 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
—20 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
7.4%20 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
3.4%20 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
—10 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
2.2%10 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
0%10 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT00521339 · Phase 2 · registry result, not featured evidence
—20 mg
NCT00521339 · Phase 2 · registry result, not featured evidence
0%20 mg/20 mg
NCT00521339 · Phase 2 · registry result, not featured evidence
14.3%20 mg/30 mg
NCT00521339 · Phase 2 · registry result, not featured evidence
0.7%0.3% foamg
NCT05028582 · Phase 3
show 1 more result
0.5%
NCT04128007 · Phase 2
Most frequent reported AEs
30 mg BIDg
upper respiratory tract infection 22.8% (placebo 2.6%)
diarrhoea 20.3% (placebo 0%)
nasopharyngitis 16.3% (placebo 3.9%)
NCT01194219 · Phase 3
show 50 more results
30 mg BID
diarrhoea 18.8% (placebo 0%)
nausea 15.7% (placebo 0%)
upper respiratory tract infection 10.2% (placebo 2.6%)
NCT01194219 · Phase 3
nausea 18.4% (placebo 3.2%)
diarrhoea 15.8% (placebo 1.6%)
nasopharyngitis 7.4% (placebo 8.1%)
NCT01232283 · Phase 3
nasopharyngitis 18.2% (placebo 8.1%)
nausea 17.9% (placebo 3.2%)
diarrhoea 16.3% (placebo 1.6%)
NCT01232283 · Phase 3
30 mg
diarrhoea 30.5% (placebo 10.8%)
nausea 21.5% (placebo 5.9%)
headache 12% (placebo 4.9%)
NCT03123471 · Phase 3
diarrhoea 31% (placebo 10.8%)
nausea 23.5% (placebo 5.9%)
headache 12.5% (placebo 4.9%)
NCT03123471 · Phase 3
diarrhoea 26.8% (placebo 10.8%)
nausea 19.4% (placebo 5.9%)
headache 9.9% (placebo 4.9%)
NCT03123471 · Phase 3
30 mg
diarrhoea 11.8% (placebo 8.3%)
nausea 7.4% (placebo 7.6%)
headache 6.6% (placebo 11%)
NCT03777436 · Phase 3
30 mg
diarrhoea 25.9% (placebo 8.3%)
headache 23.1% (placebo 11%)
nausea 22.4% (placebo 7.6%)
NCT03777436 · Phase 3
30 mg BID
diarrhoea 11.7% (placebo 10%)
psoriasis 9.9% (placebo 3.8%)
nausea 9% (placebo 2.5%)
NCT03701763 · Phase 3
30 mg BID
diarrhoea 20.5% (placebo 10%)
nausea 20.5% (placebo 2.5%)
vomiting 15.7% (placebo 2.5%)
NCT03701763 · Phase 3
20 mg BID
diarrhoea 18.2% (placebo 10%)
nausea 16.4% (placebo 2.5%)
vomiting 13.6% (placebo 2.5%)
NCT03701763 · Phase 3
20 mg BID
abdominal pain 28.8% (placebo 10%)
vomiting 20% (placebo 2.5%)
diarrhoea 18.8% (placebo 10%)
NCT03701763 · Phase 3
BID
diarrhoea 14.9% (placebo 10%)
nausea 12.7% (placebo 2.5%)
vomiting 10% (placebo 2.5%)
NCT03701763 · Phase 3
BID
abdominal pain 19.6% (placebo 10%)
diarrhoea 19.6% (placebo 10%)
nausea 19.6% (placebo 2.5%)
NCT03701763 · Phase 3
30 mg
diarrhoea 16.4% (placebo 5.1%)
headache 13.1% (placebo 5.1%)
nausea 12.8% (placebo 4.4%)
NCT03721172 · Phase 3
diarrhoea 14.3% (placebo 5.1%)
headache 12.9% (placebo 5.1%)
nausea 12.7% (placebo 4.4%)
NCT03721172 · Phase 3
covid-19 11%
nasopharyngitis 3.4%
headache 2.5%
NCT04908475 · Phase 4 · registry result, not featured evidence
covid-19 12.5%
nasopharyngitis 10.4%
hypertension 6.3%
NCT04908475 · Phase 4 · registry result, not featured evidence
covid-19 11.8%
nasopharyngitis 9.8%
upper respiratory tract infection 5.9%
NCT04908475 · Phase 4 · registry result, not featured evidence
covid-19 16.4%
nasopharyngitis 9.5%
hypertension 5.2%
NCT04908475 · Phase 4 · registry result, not featured evidence
nausea 41.7%
upper respiratory infection 25%
acute gout 16.7%
NCT03022617 · Phase 4 · registry result, not featured evidence
30 mg
nasopharyngitis 11.3% (placebo 12%)
diarrhoea 10% (placebo 6.5%)
psoriasis 9% (placebo 10.9%)
NCT03774875 · Phase 4 · registry result, not featured evidence
30 mg
diarrhoea 33% (placebo 6.5%)
headache 20% (placebo 5.4%)
nausea 20% (placebo 5.4%)
NCT03774875 · Phase 4 · registry result, not featured evidence
nausea 20%
diarrhea 15.7%
headache 15.7%
NCT03082729 · Phase 4 · registry result, not featured evidence
diarrhea 16.1%
nausea 12.9%
folliculitis 6.5%
NCT03587194 · Phase 4 · registry result, not featured evidence · combination
diarrhea 30%
nausea 30%
headache 25%
NCT03000309 · Phase 4 · registry result, not featured evidence
diarrhoea 29.3% (placebo 16.4%)
headache 20.4% (placebo 11%)
nausea 17.7% (placebo 9.6%)
NCT02425826 · Phase 4 · registry result, not featured evidence
diarrhoea 18% (placebo 18%)
headache 16% (placebo 14%)
nausea 12% (placebo 12%)
NCT02400749 · Phase 4 · registry result, not featured evidence
30 mg BID
abdominal pain 25% (placebo 12.5%)
worsening of psoriasis 12.5% (placebo 37.5%)
bronchitis 0% (placebo 12.5%)
NCT02412644 · Phase 4 · registry result, not featured evidence
30 mg BID
first degree burn 37.9% (placebo 0%)
bronchitis 3.4% (placebo 12.5%)
worsening of psoriasis 3.4% (placebo 37.5%)
NCT02412644 · Phase 4 · registry result, not featured evidence
30 mg
diarrhoea 19.1%
nausea 19.1%
nasopharyngitis 18.4%
NCT03930186 · Phase 3 · registry result, not featured evidence
30 mg
diarrhoea 14.5% (placebo 3.6%)
headache 14.5% (placebo 3.6%)
nausea 14.5% (placebo 1.2%)
NCT01690299 · Phase 3 · registry result, not featured evidence
headache 13.3% (placebo 3.6%)
diarrhoea 10.8% (placebo 3.6%)
nausea 10.8% (placebo 1.2%)
NCT01690299 · Phase 3 · registry result, not featured evidence
arthroscopic procedure 3.6%
contact dermatitis to watch 3.6%
cough 3.6%
NCT03442088 · Phase 2 · registry result, not featured evidence
30 mg
diarrhoea 50%
nausea 50%
nasopharyngitis 37.5%
NCT02576678 · Phase 2 · registry result, not featured evidence
20 mg
nausea 61.5%
headache 53.8%
abdominal pain 46.2%
NCT02576678 · Phase 2 · registry result, not featured evidence
20 mg
abdominal pain 52.4%
headache 52.4%
nausea 47.6%
NCT02576678 · Phase 2 · registry result, not featured evidence
30 mg BID
nasopharyngitis 11.8% (placebo 8.3%)
diarrhoea 9.4% (placebo 1.2%)
abdominal discomfort 7.1% (placebo 1.2%)
NCT01988103 · Phase 2 · registry result, not featured evidence
30 mg BID
nasopharyngitis 29.2% (placebo 8.3%)
diarrhoea 10% (placebo 1.2%)
abdominal discomfort 6.7% (placebo 1.2%)
NCT01988103 · Phase 2 · registry result, not featured evidence
20 mg BID
nasopharyngitis 11.8% (placebo 8.3%)
diarrhoea 8.2% (placebo 1.2%)
abdominal discomfort 1.2% (placebo 1.2%)
NCT01988103 · Phase 2 · registry result, not featured evidence
20 mg BID
nasopharyngitis 23.1% (placebo 8.3%)
diarrhoea 8.3% (placebo 1.2%)
abdominal discomfort 2.5% (placebo 1.2%)
NCT01988103 · Phase 2 · registry result, not featured evidence
30 mg BID
nausea 22.6% (placebo 8%)
upper respiratory tract infection 20.2% (placebo 4.5%)
tension headache 14.5% (placebo 8%)
NCT00773734 · Phase 2 · registry result, not featured evidence
30 mg BID
nausea 19.3% (placebo 8%)
tension headache 15.9% (placebo 8%)
upper respiratory tract infection 15.9% (placebo 4.5%)
NCT00773734 · Phase 2 · registry result, not featured evidence
20 mg BID
nausea 16.5% (placebo 8%)
upper respiratory tract infection 15.7% (placebo 4.5%)
headache 10.7% (placebo 5.7%)
NCT00773734 · Phase 2 · registry result, not featured evidence
20 mg BID
nausea 14.9% (placebo 8%)
upper respiratory tract infection 12.6% (placebo 4.5%)
headache 9.2% (placebo 5.7%)
NCT00773734 · Phase 2 · registry result, not featured evidence
10 mg BID
upper respiratory tract infection 15.7% (placebo 4.5%)
nausea 13.5% (placebo 8%)
nasopharyngitis 11.2% (placebo 8%)
NCT00773734 · Phase 2 · registry result, not featured evidence
10 mg BID
nausea 11.2% (placebo 8%)
upper respiratory tract infection 10.1% (placebo 4.5%)
nasopharyngitis 9% (placebo 8%)
NCT00773734 · Phase 2 · registry result, not featured evidence
20 mg
diarrhoea 23.3%
headache 20%
nausea 20%
NCT00521339 · Phase 2 · registry result, not featured evidence
20 mg/20 mg
corneal abrasion 25%
influenza like illness 25%
joint dislocation 25%
NCT00521339 · Phase 2 · registry result, not featured evidence
20 mg/30 mg
epistaxis 28.6%
pain in extremity 28.6%
back pain 14.3%
NCT00521339 · Phase 2 · registry result, not featured evidence
—

Notes

  1. aPopulation comparability has not been reviewed for both studies.
  2. bTreatment context has not been resolved for both arms.
  3. cAssessment timepoints differ: 16 weeks versus 8 weeks.
  4. dTrial phases differ: Phase 4 versus Phase 3.
  5. eAssessment timepoints differ: 16 weeks versus 1 weeks.
  6. fAssessment timepoints differ: 16 weeks versus 2 weeks.
  7. gPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

apremilast

sPGA 0/1 21.7% (n=562) vs 3.9% (n=282) placebo @ 16wk30 mg BID
responder rate · % of participants
NCT01194219 · Phase 3 · monotherapy
show 13 more results
22.2% (n=143) vs 6.9% (n=146) placebo @ 16wk30 mg
NCT03777436 · Phase 3
21.6% (n=297) vs 4.1% (n=298) placebo @ 16wk30 mg
NCT03721172 · Phase 3
29.6% (n=71) vs 8.8% (n=68) placebo @ 16wk30 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
33.7% (n=83) vs 12.6% (n=87) placebo @ 16wk30 mg
NCT00773734 · Phase 2 · registry result, not featured evidence
23.9% (n=71) vs 8.8% (n=68) placebo @ 16wk20 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
25% (n=80) vs 12.6% (n=87) placebo @ 16wk20 mg
NCT00773734 · Phase 2 · registry result, not featured evidence
10.5% (n=86) vs 12.6% (n=87) placebo @ 16wk10 mg
NCT00773734 · Phase 2 · registry result, not featured evidence
20.4% (n=274) vs 4.4% (n=137) placebo @ 16wk
NCT01232283 · Phase 3
33.1% (n=163) vs 11.5% (n=82) placebo @ 16wk
NCT03701763 · Phase 3
75.4% (n=118) vs 18.4% (n=234) APR @ 16wk
NCT04908475 · Phase 4 · registry result, not featured evidence
77.1% (n=83) vs 7.7% (n=78) APR @ 52wk
NCT04908475 · Phase 4 · registry result, not featured evidence
30.4% (n=148) vs 9.6% (n=73) placebo @ 16wk
NCT02425826 · Phase 4 · registry result, not featured evidence
21.7% (n=83) vs 3.6% (n=84) placebo @ 16wk
NCT01690299 · Phase 3 · registry result, not featured evidence
BSA -47.77% (n=559) vs -6.99% (n=278) placebo @ 16wk30 mg BID
absolute change · percentage points
NCT01194219 · Phase 3 · monotherapy
show 11 more results
-4.12% (n=120) vs -0.79% (n=111) placebo @ 16wk30 mg
NCT03777436 · Phase 3
-3.45% (n=261) vs -0.07% (n=249) placebo @ 16wk30 mg
NCT03721172 · Phase 3
-19.8% (n=185) vs 18.5% (n=92) placebo @ 16wk30 mg
NCT03774875 · Phase 4 · registry result, not featured evidence
-30.5% (n=85) vs 7.5% (n=84) placebo @ 16wk30 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
-50.4% (n=87) vs -8% (n=88) placebo @ 16wk30 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
-21.6% (n=85) vs 7.5% (n=84) placebo @ 16wk20 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
-38% (n=82) vs -8% (n=88) placebo @ 16wk20 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
-28.3% (n=87) vs -8% (n=88) placebo @ 16wk10 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
-48.4% (n=269) vs -6.25% (n=136) placebo @ 16wk
NCT01232283 · Phase 3
-55.44% (n=163) vs -20.56% (n=82) placebo @ 16wk
NCT03701763 · Phase 3
-47.7% (n=83) vs -16.3% (n=84) placebo @ 16wk
NCT01690299 · Phase 3 · registry result, not featured evidence
PASI -43.1% (n=85) vs -3.7% (n=84) placebo @ 16wk30 mg BID
percent change · % of baseline
NCT01988103 · Phase 2 · registry result, not featured evidence
show 8 more results
-53.2% (n=87) vs -20.3% (n=88) placebo @ 16wk30 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
-33.1% (n=85) vs -3.7% (n=84) placebo @ 16wk20 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
-45.4% (n=82) vs -20.3% (n=88) placebo @ 16wk20 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
-34% (n=87) vs -20.3% (n=88) placebo @ 16wk10 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
-52.1% (n=559) vs -16.8% (n=278) placebo @ 16wk
NCT01194219 · Phase 3 · monotherapy
-50.8% (n=269) vs -16% (n=136) placebo @ 16wk
NCT01232283 · Phase 3
-64.52% (n=163) vs -37.49% (n=82) placebo @ 16wk
NCT03701763 · Phase 3
-40.72% (n=147) vs -3.87% (n=73) placebo @ 16wk
NCT02425826 · Phase 4 · registry result, not featured evidence
PASI 50 50.6% (n=85) vs 21.4% (n=84) placebo @ 16wk30 mg BID
responder rate · % of participants
NCT01988103 · Phase 2 · registry result, not featured evidence
show 9 more results
60.2% (n=88) vs 25% (n=88) placebo @ 16wk30 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
41.2% (n=85) vs 21.4% (n=84) placebo @ 16wk20 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
47.1% (n=87) vs 25% (n=88) placebo @ 16wk20 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
38.2% (n=89) vs 25% (n=88) placebo @ 16wk10 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
58.7% (n=562) vs 17% (n=282) placebo @ 16wk
NCT01194219 · Phase 3 · monotherapy
55.5% (n=274) vs 19.7% (n=137) placebo @ 16wk
NCT01232283 · Phase 3
70.5% (n=163) vs 32.1% (n=82) placebo @ 16wk
NCT03701763 · Phase 3
53.4% (n=148) vs 24.7% (n=73) placebo @ 16wk
NCT02425826 · Phase 4 · registry result, not featured evidence
62.7% (n=83) vs 33.3% (n=84) placebo @ 16wk
NCT01690299 · Phase 3 · registry result, not featured evidence
Pruritus VAS -31.5 vs -7.3 placebo score @ 16wk30 mg BID
absolute change · score
NCT01194219 · Phase 3 · monotherapy
show 5 more results
-17.7 vs 7.1 placebo score @ 16wk30 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
-7.5 vs 7.1 placebo score @ 16wk20 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
-33.5 vs -12.2 placebo score @ 16wk
NCT01232283 · Phase 3
-13.9 vs -9.6 placebo score @ 1wk
NCT02425826 · Phase 4 · registry result, not featured evidence
-19.2 vs -10.2 placebo score @ 16wk
NCT02425826 · Phase 4 · registry result, not featured evidence
DLQI -6.6 vs -2.1 placebo score @ 16wk30 mg BID
absolute change · score
NCT01194219 · Phase 3 · monotherapy
show 11 more results
-5.3 vs -2.6 placebo score @ 16wk30 mg
NCT03777436 · Phase 3
-5.2 vs -2.4 placebo score @ 16wk30 mg
NCT03721172 · Phase 3
-8.7 vs -3.4 placebo score @ 16wk30 mg
NCT03774875 · Phase 4 · registry result, not featured evidence
-8.4 vs -3.9 placebo score @ 16wk30 mg
NCT01690299 · Phase 3 · registry result, not featured evidence
-2.2 vs 1.3 placebo score @ 16wk30 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
-4.4 vs -1.9 placebo score @ 16wk30 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
-0.5 vs 1.3 placebo score @ 16wk20 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
-5.9 vs -1.9 placebo score @ 16wk20 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
-3.2 vs -1.9 placebo score @ 16wk10 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
-6.7 vs -2.7 placebo score @ 16wk
NCT01232283 · Phase 3
-4.8 vs -2.4 placebo score @ 16wk
NCT02425826 · Phase 4 · registry result, not featured evidence
SF-36 MCS 2.28 vs -0.81 placebo score @ 16wk30 mg BID
absolute change · score
NCT01194219 · Phase 3 · monotherapy
show 7 more results
0.27 vs -1.59 placebo score @ 16wk30 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
3 vs -0.6 placebo score @ 16wk30 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
-0.71 vs -1.59 placebo score @ 16wk20 mg BID
NCT01988103 · Phase 2 · registry result, not featured evidence
2.9 vs -0.6 placebo score @ 16wk20 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
2.8 vs -0.6 placebo score @ 16wk10 mg BID
NCT00773734 · Phase 2 · registry result, not featured evidence
2.6 vs -0.03 placebo score @ 16wk
NCT01232283 · Phase 3
3.5 vs 2.6 placebo score @ 16wk
NCT01690299 · Phase 3 · registry result, not featured evidence
PASI-75 and sPGA 0 1 18.6% (n=274) vs 4.4% (n=137) placebo @ 16wk
responder rate · % of participants
NCT01232283 · Phase 3
Time to Loss of Efficacy 5.05 vs 2.86 placebo months
time to event · months
NCT01232283 · Phase 3 · converted to months from 21.9 weeks as posted
PGA 0 1 2pt Improvement 43.3% (n=201) @ 16wk
responder rate · % of participants
No placebo or comparator arm
NCT03123471 · Phase 3
Itch NRS ≥4 45.5% (n=185) @ 16wk
responder rate · % of participants
No placebo or comparator arm
NCT03123471 · Phase 3
show 4 more results
20.5% (n=185) @ 2wk
NCT03123471 · Phase 3
32.3% (n=185) @ 4wk
NCT03123471 · Phase 3
39.8% (n=185) @ 8wk
NCT03123471 · Phase 3
47% (n=185) @ 12wk
NCT03123471 · Phase 3
Scalp Itch NRS 4 47.1% (n=175) @ 16wk
responder rate · % of participants
No placebo or comparator arm
NCT03123471 · Phase 3
show 4 more results
26.1% (n=175) @ 2wk
NCT03123471 · Phase 3
37.8% (n=175) @ 4wk
NCT03123471 · Phase 3
45.6% (n=175) @ 8wk
NCT03123471 · Phase 3
46.5% (n=175) @ 12wk
NCT03123471 · Phase 3

+ 77 further endpoints in the CSV export.

Roflumilast (Zoryve foam)

Scalp IGA 66.4% (n=281) vs 27.8% (n=151) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
show 3 more results
30.4% (n=281) vs 11.7% (n=151) placebo @ 2wk0.3% foam
NCT05028582 · Phase 3
53.8% (n=281) vs 19.5% (n=151) placebo @ 4wk0.3% foam
NCT05028582 · Phase 3
59.1% (n=181) vs 11.4% (n=88) placebo @ 8wk*
NCT04128007 · Phase 2 · converted to % from 107 Participants as posted
Body IGA 45.5% (n=281) vs 20.1% (n=151) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
show 1 more result
40.3% (n=181) vs 6.8% (n=88) placebo @ 8wk*
NCT04128007 · Phase 2 · converted to % from 73 Participants as posted
Scalp Itch NRS 25.2% (n=203) vs 8% (n=123) placebo @ 2wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
show 5 more results
46.2% (n=203) vs 16.8% (n=123) placebo @ 4wk0.3% foam
NCT05028582 · Phase 3
65.3% (n=203) vs 30.3% (n=123) placebo @ 8wk0.3% foam
NCT05028582 · Phase 3
44.6% (n=166) vs 15.6% (n=90) placebo @ 2wk*
NCT04128007 · Phase 2 · converted to % from 74 Participants as posted
59% (n=166) vs 21.1% (n=90) placebo @ 4wk*
NCT04128007 · Phase 2 · converted to % from 98 Participants as posted
66.3% (n=166) vs 16.7% (n=90) placebo @ 8wk*
NCT04128007 · Phase 2 · converted to % from 110 Participants as posted
PSD Itch Pain Scaling -10.87 vs -5.75 placebo score @ 8wk0.3% foam
absolute change · score
NCT05028582 · Phase 3
PSD Itching Score Zero 31.7% (n=274) vs 10% (n=148) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
PSD Pain Score Zero 64.9% (n=274) vs 40.3% (n=148) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
PSD Scaling Score Zero 41.5% (n=274) vs 13.6% (n=148) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
PSD Total Score Zero 19.6% (n=274) vs 7.1% (n=148) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
PSSI 75 70.9% (n=281) vs 31.3% (n=151) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
show 1 more result
67.2% (n=180) vs 21.8% (n=87) placebo @ 8wk*
NCT04128007 · Phase 2 · converted to % from 121 Participants as posted
IGA 0 40% (n=281) vs 9.1% (n=151) placebo @ 8wk0.3% foam
responder rate · % of participants
NCT05028582 · Phase 3
PSD -45 vs -25.4 placebo score @ 4wk
absolute change · score
NCT04128007 · Phase 2
show 1 more result
-55 vs -27.5 placebo score @ 8wk
NCT04128007 · Phase 2
Time to PSSI-50 0.92 vs NA placebo months @ 8wk
time to event · months
NCT04128007 · Phase 2 · converted to months from 28 days as posted

+ 1 further endpoint in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: apremilast's landscape · Roflumilast (Zoryve foam)'s landscape